Clinical study of CNV treated by Fufang Xueshuantong capsules

Clinical study of CNV treated byFufang Xueshuantong capsules

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16009602

Enrollment

Unknown

Registered

2016-10-25

Start date

2015-11-09

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

choroidal neovascularization

Interventions

trial group:Anti VEGF drug

controlled group:Anti VEGF drug and placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Eyes examined include: the naked eye eyesight, best corrected visual acuity, intraocular pressure, fundus examination, fundus color photography and fundus fluorescence angiography; Physical examination including blood pressure, blood sugar, blood fat, liver function, renal function, etc; 2. Aged 18 years old and elder male and female; 3. Determined by fundus fluorescence angiography for CNV.

Exclusion criteria

Exclusion criteria: Have the following any one,which is rule out (1)The patients that allergy to any components of Fufang Xueshuantong capsules; (2)The severe liver function damage(Elevated bilirubin, liver decompensation); (3)Mental disorders such as cognitive impairment (4)Pregnancy and lactation,women of childbearing age to disagree contraceptive measures taken during the test;

Design outcomes

Primary

Measure	Time frame
BCVA;optic coherence tomography;	—

Countries

China

Contacts

Public ContactLiu Qinghuai

The First Affiliated Hospital of Nanjing Medical University

liuqh0545@126.com+86 13901585755

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026